Expertise in
16
conditions

Dr. Xinglei N. Shen

Kansas University Physicians Inc
Kansas City, KS
Expertise in
16
conditions
Specialties:Radiation Oncology
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
OverviewInsuranceLocationsClinical Research

Overview

Xinglei Shen is a Radiation Oncologist in Kansas City, Kansas. Dr. Shen is highly rated in 16 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Prostatectomy, and Orchiectomy. Dr. Shen is currently accepting new patients.

His clinical research consists of co-authoring 51 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in KS
Hospital Affiliations
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Medica
  •  Blue Cross Blue Shield
  •  Oscar
  •  Humana

Locations

KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 2
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
View 8 Less Clinical Trials

51 Total Publications

Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer.
Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer.
Journal: World journal of oncology
Published: August 13, 2024
Similar Doctors
Expertise in
49
conditions
Dr. Fen W. Wang
Radiation Oncology
Expertise in
49
conditions
Dr. Fen W. Wang
Radiation Oncology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
Languages Spoken:
English, German, Mandarin, Zhuang
See accepted insurances
Accepting New Patients
Offers Telehealth

Fen Wang is a Radiation Oncologist in Kansas City, Kansas. Dr. Wang is highly rated in 49 conditions, according to our data. His top areas of expertise are Lung Cancer, Meningioma, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Endovascular Embolization. Dr. Wang is currently accepting new patients.

Expertise in
36
conditions
Dr. Ronny L. Rotondo
Radiation Oncology
Expertise in
36
conditions
Dr. Ronny L. Rotondo
Radiation Oncology

Kansas University Physicians Inc

2790 Clay Edwards Dr, Suite 405, 
North Kansas City, MO 
 (7.1 mi)
913-588-1227
Languages Spoken:
English, French, Italian, Japanese, Spanish, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronny Rotondo is a Radiation Oncologist in North Kansas City, Missouri. Dr. Rotondo is highly rated in 36 conditions, according to our data. His top areas of expertise are Chordoma, Adult Soft Tissue Sarcoma, Bone Tumor, and Ewing Sarcoma. Dr. Rotondo is currently accepting new patients.

Expertise in
3
conditions
Dr. Julia R. White
Radiation Oncology
Expertise in
3
conditions
Dr. Julia R. White
Radiation Oncology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julia White is a Radiation Oncologist in Kansas City, Kansas. Dr. White is highly rated in 3 conditions, according to our data. Her top areas of expertise are Breast Cancer, Angiosarcoma, Intraductal Papilloma, and HER-2 Positive Breast Cancer. Dr. White is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile